FDA Approves LEUPROLIDE ACETATE — Eugia US LLC

# FDA Approves Eugia US LLC's Generic Leuprolide Acetate Eugia US LLC received FDA approval for its generic leuprolide acetate formulation, marking another entry into the competitive hormone therapy market that is expected to increase price competition and improve patient access to this widely used treatment for prostate cancer, endometriosis, and uterine fibroids. The approval could pressure pricing for branded leuprolide products while potentially strengthening Eugia's portfolio in the oncology and women's health segments.